Document is current
Any future updates will be listed below
-
Authors
Moran, Lissa
Ondocsin, Jeff
Outram, Simon
Ciccarone, Daniel
Werb, Daniel
Holm, Nicole
Arnold, Emily A.
-
Funding
Funding for this research was provided by:
California HIV/AIDS Research Program (H21PC3238, H21PC3238, H21PC3238, H21PC3238, H21PC3238)
- License Information
-
More Information
Article History
Received: 23 January 2024
Accepted: 2 May 2024
First Online: 11 May 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and informed consent was obtained from all subjects involved in the study. The study protocol and consent procedures were reviewed and approved by the UCSF IRB (#22-36640) on 12 September 2022.
: Not applicable.
: D.W. is a founder of DoseCheck, a commercial entity that is developing a mobile drug checking technology. D.C. reports the following relevant financial relationships during the past 12 months: (1) he is a scientific advisor to Celero Systems; and (2) he has been retained as an expert witness in ongoing prescription opioid litigation by Motley Rice, LLP. The remaining authors have no relevant financial or non-financial interests to disclose. The remaining authors have no relevant financial or non-financial interests to disclose.
